Artrya is a global medical technology company that is leading the world in cardiac image analysis
Investor information
Beating heart disease
Artrya (ASX:AYA) is changing how the world diagnoses and therefore treats coronary artery disease. We partner with healthcare delivery systems to help implement new cardiac care models that can rule out (or in) coronary artery disease, at speed, for patients presenting with chest pain. We are doing it in a way that is better for patients, healthcare professionals and health systems. Artrya’s software-as-a-medical-device, Salix Coronary Anatomy, is an AI-based solution that quickly analyzes cardiac CT scans to assist clinicians in accurately determining the extent of atherosclerotic plaque as well as plaque characteristics for patients who may be at risk of heart attack.
Sign up to receive investor communications
Company Details
Name:
Artrya Limited
Incorporated:
ACN 624 005 741
Business description:
AI-based coronary artery disease Diagnostic support software
Registered office:
1257 Hay St West, Perth, Western Australia, 6005
Auditor:
KPMG. 235 St George’s Terrace, Perth, WA, 6000
Contact:
investors@artrya.com
Company Contacts
Company Secretary:
Kevin Hart
companysecretary@artrya.com (Ph: 08 9316 9100)
Media and Communications:
Rama Razy
rama.razy@automicgroup.com.au (Ph: +61 498 440 142)
Investor Relations:
Danny Younis
danny.younis@automicgroup.com.au (Ph: +61 420 293 042)
Complaints:
contact@artrya.com